ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI’s George Khoury Dies; Panel to Meet June 22 In Pittsburgh; Rosemary Mackey To Leave MDA

May 8, 1987

IOM Report Says Smoking Bans Cut Heart Attack Risk

October 23, 2009

In Brief: William Peters To Leave Duke To Head Michigan Cancer Foundation, Prentis Center

April 7, 1995

Varmus Wins ASCO’s Science Of Oncology Award; Sawyers To Give Karnofsky Lecture.

January 28, 2005

NCI’s caBIG to Expand For Clinical Informatics Projects.

January 26, 2007

Pharmaceutical Industry: IVAX Official Broder Objects To Orphan Drug Policies of FDA

May 9, 1997